Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin J Am Soc Nephrol. 2006 Nov;1(6):1331-41. Epub 2006 Oct 11.

Light-chain (AL) amyloidosis: diagnosis and treatment.

Author information

1
Department of Medicine, Section of Hematology/Oncology, Boston University Medical Center, Boston, Massachusetts, USA. vaishali.sanchorawala@bmc.org

Abstract

Light-chain (AL) amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. The disease often is difficult to recognize because of its broad range of manifestations and what often are vague symptoms. The clinical syndromes at presentation include nephrotic-range proteinuria with or without renal dysfunction, hepatomegaly, congestive heart failure, and autonomic or sensory neuropathy. Recent diagnostic and prognostic advances include the serum free light-chain assay, cardiac magnetic resonance imaging, and serologic cardiac biomarkers. Treatment strategies that have evolved during the past decade are prolonging survival and preserving organ function in patients with this disease. This review outlines approaches to diagnosis, assessment of disease severity, and treatment of AL amyloidosis.

PMID:
17699366
DOI:
10.2215/CJN.02740806
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center